-
公开(公告)号:WO2022263556A1
公开(公告)日:2022-12-22
申请号:PCT/EP2022/066390
申请日:2022-06-15
Applicant: UNIVERSITA' DEGLI STUDI DI PADOVA
Inventor: GANDIN, Valentina , MARZANO, Cristina , PORCHIA, Marina , TISATO, Francesco
IPC: C07F9/50 , A61P35/00 , C07F9/6544 , C07F9/6536 , C07F9/6509
Abstract: The invention relates to a Cu(l) complex of Formula (I), wherein L is a ligand of Formula (II), wherein n1, n2, n3 are independently to each other, an integer from 0 to 1, A1, A2 and A3 are independently from each other,- a phenyl optionally substituted with (C1-C3)alkoxy, (C1-C3)alkyl, F, formyl, carboxyl, sulphonyl hydroxyl, hydroxyl, methoxy(C1-C3)alkoxy or - an heterocyclic ring selected from piperazinyl, morpholynyl, thiomorpholynyl, optionally substituted with (C1-C3)alkyl, where the heterocyclic ring is linked with the nitrogen atom to -CH2- residue, with the proviso that when A1, A2 or A3 is optionally substituted phenyl, then n1, n2 or n3, respectively, is 0, and when A1, A2 or A3 is optionally substituted heterocyclic ring, then n1, n2 or n3, respectively, is 1, for use in the treatment of tumours.
-
2.ALKYNYL PHOSPHINE GOLD COMPLEXES FOR TREATING BACTERIAL INFECTIONS 审中-公开
Title translation: 烷基磷黄金配合物治疗细菌感染公开(公告)号:WO2017093544A1
公开(公告)日:2017-06-08
申请号:PCT/EP2016/079680
申请日:2016-12-02
Applicant: AUSPHERIX LIMITED
Inventor: HOLMES, Ian , NAYLOR, Alan , ALBER, Dagmar , POWELL, Jonathan Raymond , MAJOR, Meriel Ruth , NEGOITA-GIRAS, Gabriel , ALLEN, Daniel Rees
IPC: C07F9/50 , A61L29/00 , A61K33/24 , C07F9/572 , C07F9/58 , C07F9/6509 , C07F9/6512 , C07F9/6533 , C07F9/6544 , C07F9/6561 , C07F9/6568 , C07F9/6571 , C07F9/6581
CPC classification number: C07F9/5045 , A61K33/24 , C07F9/5725 , C07F9/5728 , C07F9/585 , C07F9/650929 , C07F9/65125 , C07F9/6533 , C07F9/6544 , C07F9/6561 , C07F9/65683 , C07F9/657163 , C07F9/6581
Abstract: A compound of formula (I) for use in the prevention or treatment of a bacterial infection.
Abstract translation: 式(I)化合物用于预防或治疗细菌感染。 p> p>
-
公开(公告)号:WO2011126045A1
公开(公告)日:2011-10-13
申请号:PCT/JP2011/058701
申请日:2011-04-06
Applicant: 日本化学工業株式会社 , 間山 大輔
Inventor: 間山 大輔
IPC: C07F9/6509 , C07B53/00 , C07F9/50 , C07F5/02 , C07F19/00
CPC classification number: C07F9/65683 , C07B53/00 , C07F9/5036 , C07F9/650982
Abstract: 工業的に有利であり、異性体のいずれをも容易に製造し得る光学活性な2,3-ビスホスフィノピラジン誘導体の製造方法であり、下記工程I、II及びIIIにより、一般式(A)で表される光学活性な2,3-ビスホスフィノピラジン誘導体を製造する。下記式中、R 1 及びR 2 は、それらが存在することによりリン原子上に不斉を発現させるか又はリン原子が不斉面の一点をなす一対の基であり、それぞれ水素原子、炭化水素基又は置換炭化水素基を示し、R 3 は不斉炭化水素基又は置換不斉炭化水素基を示し、R 4 及びR 5 は、水素原子又はアルキル基を示し、互いに結合して飽和又は不飽和の環を形成していてもよく、Xはハロゲン原子を示す。
Abstract translation: 提供了一种制备光学活性2,3-双膦酰基吡嗪衍生物的方法,其在工业上是有利的,通过其可以容易地制备任何异构体。 具体提供的是制备由通式(A)表示的光学活性2,3-双膦酰基吡嗪衍生物的方法,其包括以下步骤(I),(II)和(III)。 在这些式中,R 1和R 2是在磷原子上产生不对称或使磷原子在不对称平面上有一个点的一对基团,分别是氢,烃基或取代的烃基; R3是不对称烃基或取代的不对称烃基; R4和R5各自为氢或烷基,或者R4和R5可以结合形成饱和或不饱和的环; X为卤素原子。
-
公开(公告)号:WO2009133687A1
公开(公告)日:2009-11-05
申请号:PCT/JP2009/001907
申请日:2009-04-27
IPC: C07D277/20 , A61K31/415 , A61K31/4155 , A61K31/42 , A61K31/426 , A61K31/428 , A61K31/433 , A61K31/437 , A61K31/44 , A61K31/454 , A61K31/496 , A61K31/4965 , A61K31/497 , A61K31/5377 , A61P3/10 , A61P43/00 , C07D213/75 , C07D231/38 , C07D241/20 , C07D261/14 , C07D277/44 , C07D277/82 , C07D285/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D417/04 , C07D417/12 , C07D513/04 , C07F9/6509 , C07F9/6539
CPC classification number: C07C309/77 , C07C2601/02 , C07C2601/08 , C07D213/75 , C07D231/38 , C07D241/20 , C07D261/14 , C07D277/20 , C07D277/44 , C07D277/82 , C07D285/08 , C07D405/04 , C07D405/06 , C07D405/12 , C07D417/04 , C07D417/12 , C07D513/04 , C07F9/5442 , C07F9/650964 , C07F9/6539
Abstract: 【課題】 血糖降下作用を有する化合物を提供し、糖尿病、肥満などの治療又は予防に役立てることを目的とする。 【解決手段】 一般式(1) (式中、R 1 及びR 2 は、同一又は異なって水素原子、ハロゲン原子、アミノ基、水酸基、ヒドロキシアミノ基、ニトロ基、シアノ基、スルファモイル基、C 1 ~C 6 のアルキル基、C 1 ~C 6 のアルコキシ基、C 1 ~C 6 のアルキルスルファニル基、C 1 ~C 6 のアルキルスルフィニル基、C 1 ~C 6 のアルキルスルホニル基又はC 1 ~C 6 アルコキシ-C 1 ~C 6 アルキルスルホニル基を示し、Aは置換基を有してもよいヘテロアリール基を示す。)で表される化合物又は薬学的に許容されるその塩。 【化1】
Abstract translation: 公开了具有抗高血糖活性的化合物,其可用于治疗或预防糖尿病,肥胖症等。 具体公开的是由通式(1)表示的化合物[其中R 1和R 2独立地表示氢原子,卤素原子,氨基,羟基,羟基氨基,硝基,氰基,氨磺酰基 ,C1-C6烷基,C1-C6烷氧基,C1-C6烷基硫烷基,C1-C6烷基亚磺酰基,C1-C6烷基磺酰基或(C1-C6烷氧基) - (C1-C6烷基磺酰基) 组; A表示可以具有取代基的杂芳基]或其药学上可接受的盐。
-
5.METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS 审中-公开
Title translation: 用于鉴定抗HIV治疗化合物的方法和组合物公开(公告)号:WO2005064008A9
公开(公告)日:2006-09-28
申请号:PCT/US2004042991
申请日:2004-12-22
Applicant: GILEAD SCIENCES INC , ARIMILLI MURTY N , BECKER MARK M , BIRKUS GABRIEL , BRYANT CLIFFORD , CHEN JAMES M , CHEN XIAOWU , CIHLAR TOMAS , DASTGAH AZAR , EISENBERG EUGENE J , FARDIS MARIA , HATADA MARCOS , HE GONG-XIN , JIN HAOLUN , KIM CHOUNG U , LEE WILLIAM A , LEE CHRISTOPHER P , LIN KUEI-YING , LIU HONGTAO , MACKMAN RICHARD L , MCDERMOTT MARTIN J , MITCHELL MICHAEL L , NELSON PETER H , PYUN HYUNG-JUNG , ROWE TANISHA D , SPARACINO MARK , SWAMINATHAN SUNDARAMOORTHI , TARIO JAMES D , WANG JIANYING , WILLIAMS MATTHEW A , XU LIANHONG , YANG ZHENG-YU , YU RICHARD H , ZHANG JIANCUN , ZHANG LIJUN
Inventor: ARIMILLI MURTY N , BECKER MARK M , BIRKUS GABRIEL , BRYANT CLIFFORD , CHEN JAMES M , CHEN XIAOWU , CIHLAR TOMAS , DASTGAH AZAR , EISENBERG EUGENE J , FARDIS MARIA , HATADA MARCOS , HE GONG-XIN , JIN HAOLUN , KIM CHOUNG U , LEE WILLIAM A , LEE CHRISTOPHER P , LIN KUEI-YING , LIU HONGTAO , MACKMAN RICHARD L , MCDERMOTT MARTIN J , MITCHELL MICHAEL L , NELSON PETER H , PYUN HYUNG-JUNG , ROWE TANISHA D , SPARACINO MARK , SWAMINATHAN SUNDARAMOORTHI , TARIO JAMES D , WANG JIANYING , WILLIAMS MATTHEW A , XU LIANHONG , YANG ZHENG-YU , YU RICHARD H , ZHANG JIANCUN , ZHANG LIJUN
IPC: C12N9/99 , C12Q1/44 , A61K31/4155 , A61K31/66 , A61K31/665 , A61K31/675 , A61P31/18 , A61P43/00 , C07D213/75 , C07D213/85 , C07D231/12 , C07D231/20 , C07D233/42 , C07D239/48 , C07D239/80 , C07D243/04 , C07D265/18 , C07D307/68 , C07D401/06 , C07D403/06 , C07D471/14 , C07D491/04 , C07F20060101 , C07F9/02 , C07F9/38 , C07F9/40 , C07F9/44 , C07F9/58 , C07F9/62 , C07F9/645 , C07F9/6506 , C07F9/6509 , C07F9/6512 , C07F9/653 , C07F9/6533 , C07F9/655 , C07F9/6558 , C07F9/6561 , C07F9/6584 , C12N9/16 , C12Q1/18 , C12Q1/37 , C12Q1/70 , G01N33/04 , G01N33/50
CPC classification number: A61K31/66 , A61K31/675 , C07D213/75 , C07D213/85 , C07D231/12 , C07D231/20 , C07D233/42 , C07D239/49 , C07D239/80 , C07D243/04 , C07D265/18 , C07D307/68 , C07D401/06 , C07D403/06 , C07D471/14 , C07D491/04 , C07F9/4006 , C07F9/582 , C07F9/588 , C07F9/645 , C07F9/65061 , C07F9/65062 , C07F9/65067 , C07F9/650911 , C07F9/650917 , C07F9/650947 , C07F9/65121 , C07F9/65122 , C07F9/65127 , C07F9/65128 , C07F9/65335 , C07F9/65515 , C07F9/65583 , C07F9/6561 , C12N9/16 , C12Q1/18 , C12Q1/37 , C12Q1/44 , C40B40/04 , G01N33/5038 , G01N2333/16 , G01N2500/04 , G01N2500/20
Abstract: Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.
Abstract translation: 提供了用于鉴定被羧基酯或膦酸酯基取代的抗HIV治疗化合物的方法。 可以使用新型GS-7340酯水解酶来筛选这些化合物的文库。 还提供了与GS-7340酯水解酶有关的组合物和方法。
-
6.(+)-TRANS-ISOMERS OF (1-PHOSPHONOMETHOXY-2-ALKYLCYCLOPROPYL) METHYL NUCLEOSIDE DERIVATIVES, PROCESS FOR THE PREPARATION OF STEREOISOMERS THEREOF, AND USE OF ANTIVIRAL AGENTS THEREOF 审中-公开
Title translation: (+) - (1-膦酰基-2-甲基-2-环丙基)甲基核苷衍生物的转移异构体,其制备方法及其抗病毒剂的用途公开(公告)号:WO2004029064A8
公开(公告)日:2005-05-19
申请号:PCT/KR0301932
申请日:2003-09-22
Applicant: LG LIFE SCIENCES LTD , CHOI JONG-RYOO , HWANG JAE-TAEG , CHO DONG-GYU , ROH KEE-YOON , KIM CHUN-HYUNG , KIM CHUNG-MI , HAN MIN-JOON , KIM JEONG-MIN , CHO WOO-YOUNG , KIM GYOUNG-WON , AHN SINBYOUNG
Inventor: CHOI JONG-RYOO , HWANG JAE-TAEG , CHO DONG-GYU , ROH KEE-YOON , KIM CHUN-HYUNG , KIM CHUNG-MI , HAN MIN-JOON , KIM JEONG-MIN , CHO WOO-YOUNG , KIM GYOUNG-WON , AHN SINBYOUNG
IPC: C07F9/40 , C07F9/6512 , C07F9/6561 , A61K31/675 , C07F9/6509
CPC classification number: C07F9/65616 , C07F9/4006 , C07F9/65121
Abstract: The present invention relates to (+)-trans-isomers of (1-phosphonomethoxy-2- alkylcyclopropyl)methyl nucleoside derivatives of the formula (1) which are useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable saltss, hydrates, or solvates thereof, and processes for the preparation of stereoisomers of the compounds of the formula (1), and a composition for the treatment of viral diseases (particularly, against hepatitis B virus) comprising (+)-trans-isomer of the compound of the formula (1), pharmaceutically acceptable salt, hydrate, or solvate thereof as an active substance.
Abstract translation: 本发明涉及可用作抗病毒剂(特别是针对乙型肝炎病毒)的式(1)的(1-膦基甲氧基-2-烷基环丙基)甲基核苷衍生物的(+) - 反式异构体,其药学上可接受的盐 ,水合物或溶剂合物,以及制备式(1)化合物的立体异构体的方法和用于治疗病毒性疾病(特别是针对乙型肝炎病毒)的组合物,其包含(+) - 反式异构体 式(1)的化合物,其药学上可接受的盐,水合物或溶剂合物作为活性物质。
-
公开(公告)号:WO03037887A8
公开(公告)日:2005-03-17
申请号:PCT/SE0201988
申请日:2002-11-01
Applicant: ASTRAZENECA AB , ANGST CHRISTOF , HAEBERLEIN MARKUS , HILL DANIEL , JACOBS ROBERT , MOORE GARY , PIERSON EDWARD , SHENVI ASHOKKUMAR BHIKKAPPA
Inventor: ANGST CHRISTOF , HAEBERLEIN MARKUS , HILL DANIEL , JACOBS ROBERT , MOORE GARY , PIERSON EDWARD , SHENVI ASHOKKUMAR BHIKKAPPA
IPC: C07D401/02 , A61K31/4725 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/675 , A61P1/00 , A61P3/04 , A61P5/00 , A61P9/00 , A61P15/10 , A61P21/00 , A61P25/00 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/24 , A61P25/28 , C07D217/04 , C07D217/06 , C07D217/12 , C07D217/24 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/06 , C07D413/10 , C07D413/12 , C07D417/12 , C07F9/6509
CPC classification number: C07D401/04 , C07D217/04 , C07D217/06 , C07D401/12 , C07D405/06 , C07D413/10 , C07D413/12 , C07D417/12
Abstract: Provided herein is a compound of the formula (I), wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.
Abstract translation: 本文提供了式(I)的化合物,其中所述化合物可用于治疗精神障碍,包括但不限于抑郁症,广泛性焦虑症,进食障碍,痴呆症,惊恐障碍和睡眠障碍。 该化合物还可用于治疗胃肠道疾病,心血管调节,运动障碍,内分泌障碍,血管痉挛和性功能障碍。 这些化合物是5HT1B和5HT1D拮抗剂。
-
8.CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS 审中-公开
Title translation: 艾滋病毒蛋白酶抑制剂化合物的磷酸酯类似物的细胞积累公开(公告)号:WO03090690A2
公开(公告)日:2003-11-06
申请号:PCT/US0312901
申请日:2003-04-25
Applicant: GILEAD SCIENCES INC , ARIMILLI MURTY N , BECKER MARK M , BRYANT CLIFFORD , CHEN JAMES M , CHEN XIAOWU
Inventor: ARIMILLI MURTY N , BECKER MARK M , BRYANT CLIFFORD , CHEN JAMES M , CHEN XIAOWU
IPC: C12N9/99 , A61K31/4155 , A61K31/66 , A61K31/665 , A61K31/675 , A61P31/18 , A61P43/00 , C07D213/75 , C07D213/85 , C07D231/12 , C07D231/20 , C07D233/42 , C07D239/48 , C07D239/80 , C07D243/04 , C07D265/18 , C07D307/68 , C07D401/06 , C07D403/06 , C07D471/14 , C07D491/04 , C07F20060101 , C07F9/02 , C07F9/38 , C07F9/40 , C07F9/44 , C07F9/58 , C07F9/62 , C07F9/645 , C07F9/6506 , C07F9/6509 , C07F9/6512 , C07F9/653 , C07F9/6533 , C07F9/655 , C07F9/6558 , C07F9/6561 , C07F9/6584 , C12N9/16 , C12Q1/18 , C12Q1/37 , C12Q1/44 , C12Q1/70 , G01N33/04 , G01N33/50 , A61K
CPC classification number: A61K31/66 , A61K31/675 , C07D213/75 , C07D213/85 , C07D231/12 , C07D231/20 , C07D233/42 , C07D239/49 , C07D239/80 , C07D243/04 , C07D265/18 , C07D307/68 , C07D401/06 , C07D403/06 , C07D471/14 , C07D491/04 , C07F9/4006 , C07F9/582 , C07F9/588 , C07F9/645 , C07F9/65061 , C07F9/65062 , C07F9/65067 , C07F9/650911 , C07F9/650917 , C07F9/650947 , C07F9/65121 , C07F9/65122 , C07F9/65127 , C07F9/65128 , C07F9/65335 , C07F9/65515 , C07F9/65583 , C07F9/6561 , C12N9/16 , C12Q1/18 , C12Q1/37 , C12Q1/44 , C40B40/04 , G01N33/5038 , G01N2333/16 , G01N2500/04
Abstract: Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit 5 HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.
Abstract translation: 公开了具有用作治疗剂和用于其它工业目的的具有HIV蛋白酶抑制性质的膦酸酯取代的化合物。 该组合物抑制5种HIV蛋白酶活性和/或用于治疗AIDS和其它抗病毒感染以及用于检测HIV蛋白酶的测定。
-
9.
公开(公告)号:WO01062766A1
公开(公告)日:2001-08-30
申请号:PCT/US2000/022703
申请日:2000-08-18
IPC: C09K21/08 , C07F9/24 , C07F9/6509 , C07F9/6518 , C07F9/6574 , C09K21/10 , C09K21/12 , C07F9/22
CPC classification number: C07F9/65181 , C07F9/2458 , C07F9/650958
Abstract: Sterically hindered phosphoramidates such as N,N'-bis[di-(2,6-xylenoxy)phosphinyl]piperazine are prepared by the reaction of a sterically hindered diaryl chlorophosphate, such as di-(2,6-xylyl) chlorophosphate, with a basic nitrogen compound containing at least two basic N-H groups, preferably a heterocyclic compound such as piperazine, in the presence of calcium oxide as an acid acceptor. The reaction is conducted in the presence of at least one dipolar aprotic solvent.
Abstract translation: 通过空间位阻氯磷酸二芳基酯如氯化磷酸二(2,6-二甲苯基酯)与氯化磷酸二(2,6-二甲苯基)酯反应制备N,N'-双[二 - (2,6-二甲苯氧基)氧膦基]哌嗪 在氧化钙作为酸受体的存在下,含有至少两个碱性NH基团,优选杂环化合物如哌嗪的碱性氮化合物。 反应在至少一种偶极非质子溶剂的存在下进行。
-
10.
公开(公告)号:WO01047935A2
公开(公告)日:2001-07-05
申请号:PCT/IB2000/002071
申请日:2000-12-22
IPC: A61K31/665 , A61K31/675 , A61P3/10 , A61P43/00 , C07F9/44 , C07F9/58 , C07F9/6509 , C07F9/6512 , C07F9/653 , C07F9/6539 , C07F9/6541 , C07F9/655 , C07F9/6561 , C07F
CPC classification number: C07F9/6561 , C07F9/4465 , C07F9/65515
Abstract: Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula (IA) and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.
Abstract translation: 式(IA)的FBP酶抑制剂的新型双酰胺基膦酸酯前药及其在治疗与血糖升高相关的糖尿病和其它病症中的用途。
-
-
-
-
-
-
-
-
-